New Delhi, Jun 10 (PTI) India Ratings and Research (Ind-Ra) on Wednesday said the country's pharmaceutical sector is expected to grow 3-5 per cent year-on-year in the current financial year despite coronavirus-led lockdown.
The domestic rating agency also expects monthly revenue improvements of drug firms from June.
Also Read | Nintendo's 3 Lakh Accounts Breached by Hackers Since Early April of This Year.
"Additionally, the seasonality in the Indian domestic business will support the recovery. Also, the continuous rise in the number of COVID-19 cases in the country will result in further volume growth in related therapies," Ind-Ra noted.
Besides, pharma companies' large cash balances and sufficient headroom under debt covenants along with diversified funding sources will mitigate any impact of the ongoing lockdown, it added.
Also Read | OnePlus Z Affordable Smartphone Likely To Be Called 'Nord By OnePlus': Report.
The COVID-19 impact on the pharmaceutical sector has been less pronounced than observed in other sectors, as it falls under the essential service category and is exempt from restrictions under the nationwide lockdown, the rating agency said.
Manufacturing volumes after declining to 50-60 per cent in April, given the strict lockdown, has improved significantly to 60-80 per cent of the original capacities during the May-June period so far, Ind-Ra noted.
However, the companies have refrained from new launches during the lockdown due to lack of effective marketing campaigns, the rating agency said.
Further, companies may take price hikes on non-DPCO (Drug Price Control Order) products up to 8 per cent unlike the earlier average price hike of 5 per cent (max limit 10 per cent) due to an increase in raw material cost and the additional cost incurred towards raw materials, logistics and manpower, it added.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)













Quickly


